PL1603564T3 - Zastosowanie pochodnych pirydyn-2-ylo metyloamin do wytwarzania leku do leczenia objawów przewlekłego bólu neuropatycznego lub psychogennego - Google Patents

Zastosowanie pochodnych pirydyn-2-ylo metyloamin do wytwarzania leku do leczenia objawów przewlekłego bólu neuropatycznego lub psychogennego

Info

Publication number
PL1603564T3
PL1603564T3 PL04720637T PL04720637T PL1603564T3 PL 1603564 T3 PL1603564 T3 PL 1603564T3 PL 04720637 T PL04720637 T PL 04720637T PL 04720637 T PL04720637 T PL 04720637T PL 1603564 T3 PL1603564 T3 PL 1603564T3
Authority
PL
Poland
Prior art keywords
pyridin
treatment
analgesic
alkyl
methyl
Prior art date
Application number
PL04720637T
Other languages
English (en)
Inventor
Francis Colpaert
Bernard Vacher
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of PL1603564T3 publication Critical patent/PL1603564T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL04720637T 2003-03-13 2004-03-15 Zastosowanie pochodnych pirydyn-2-ylo metyloamin do wytwarzania leku do leczenia objawów przewlekłego bólu neuropatycznego lub psychogennego PL1603564T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0303099A FR2852244B1 (fr) 2003-03-13 2003-03-13 Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene
PCT/FR2004/000630 WO2004083171A2 (fr) 2003-03-13 2004-03-15 Utilisation de derives de pyridin-2-yl-methylamine pour le traitement des symptomes de la douleur chronique neuropathique ou psychogene
EP04720637A EP1603564B1 (fr) 2003-03-13 2004-03-15 Utilisation de derives de pyridin-2-yl-methylamine pour le traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene

Publications (1)

Publication Number Publication Date
PL1603564T3 true PL1603564T3 (pl) 2007-12-31

Family

ID=32893267

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04720637T PL1603564T3 (pl) 2003-03-13 2004-03-15 Zastosowanie pochodnych pirydyn-2-ylo metyloamin do wytwarzania leku do leczenia objawów przewlekłego bólu neuropatycznego lub psychogennego

Country Status (25)

Country Link
US (1) US8609694B2 (pl)
EP (1) EP1603564B1 (pl)
JP (1) JP4684994B2 (pl)
KR (1) KR101100002B1 (pl)
CN (1) CN1761467B (pl)
AT (1) ATE366111T1 (pl)
AU (1) AU2004222051B2 (pl)
BR (1) BRPI0408293A (pl)
CA (1) CA2518591C (pl)
CY (1) CY1106900T1 (pl)
DE (1) DE602004007364T2 (pl)
DK (1) DK1603564T3 (pl)
ES (1) ES2289494T3 (pl)
FR (1) FR2852244B1 (pl)
HK (1) HK1079120A1 (pl)
IL (1) IL170743A (pl)
MX (1) MXPA05009782A (pl)
NO (1) NO334997B1 (pl)
NZ (1) NZ542461A (pl)
PL (1) PL1603564T3 (pl)
PT (1) PT1603564E (pl)
RU (1) RU2359674C2 (pl)
UA (1) UA81023C2 (pl)
WO (1) WO2004083171A2 (pl)
ZA (1) ZA200507634B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071778B2 (en) 2006-07-27 2011-12-06 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009096941A1 (en) * 2008-01-28 2009-08-06 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in cns disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020346A (en) 1995-01-12 2000-02-01 Glaxo Wellcome Inc. Piperidine derivatives having tachykinin antagonist activity
FR2755967B1 (fr) * 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
FR2784378B1 (fr) * 1998-10-09 2000-12-29 Pf Medicament Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
FR2840900B1 (fr) * 2002-06-18 2005-02-25 Pf Medicament Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments

Also Published As

Publication number Publication date
WO2004083171A3 (fr) 2004-12-23
AU2004222051A1 (en) 2004-09-30
DE602004007364D1 (de) 2007-08-16
CA2518591A1 (fr) 2004-09-30
CN1761467B (zh) 2011-09-21
DK1603564T3 (da) 2007-10-01
JP2006520370A (ja) 2006-09-07
ZA200507634B (en) 2006-06-28
AU2004222051B2 (en) 2009-01-15
RU2359674C2 (ru) 2009-06-27
JP4684994B2 (ja) 2011-05-18
FR2852244A1 (fr) 2004-09-17
NZ542461A (en) 2008-10-31
CN1761467A (zh) 2006-04-19
EP1603564A2 (fr) 2005-12-14
IL170743A (en) 2011-11-30
IL170743A0 (en) 2009-02-11
CA2518591C (fr) 2012-05-15
NO20054673L (no) 2005-10-11
MXPA05009782A (es) 2005-12-05
CY1106900T1 (el) 2012-09-26
DE602004007364T2 (de) 2008-03-06
RU2005131615A (ru) 2006-02-10
ATE366111T1 (de) 2007-07-15
BRPI0408293A (pt) 2006-03-07
KR101100002B1 (ko) 2011-12-28
FR2852244B1 (fr) 2007-09-07
US20060241141A1 (en) 2006-10-26
WO2004083171A2 (fr) 2004-09-30
NO334997B1 (no) 2014-08-18
ES2289494T3 (es) 2008-02-01
KR20050106120A (ko) 2005-11-08
PT1603564E (pt) 2007-09-24
UA81023C2 (en) 2007-11-26
US8609694B2 (en) 2013-12-17
EP1603564B1 (fr) 2007-07-04
HK1079120A1 (en) 2006-03-31

Similar Documents

Publication Publication Date Title
KR101855357B1 (ko) 오피오이드 유도성 통각과민에서의 시그마 리간드의 용도
ES2955490T3 (es) Métodos y composiciones para potenciar la acción de los analgésicos opioides mediante el uso de alcaloides de la iboga
TWI629984B (zh) σ配體在與間質性膀胱炎／膀胱疼痛綜合徵（ＩＣ／ＢＰＳ）相關的疼痛的預防和治療中的應用
UA112638C2 (uk) Застосування сигма-лігандів від болю при раку кісток
WO2006049312A1 (ja) 神経因性疼痛治療剤
KR20110021823A (ko) 진통 내성 억제제
JP4706636B2 (ja) 鎮痛剤
Overstreet et al. Selective inhibition of alcohol intake in diverse alcohol‐preferring rat strains by the 5‐HT2A antagonists amperozide and FG 5974
KR20060121178A (ko) 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
US20080300262A1 (en) Combination Therapy for Relief of Pain
Horita et al. Effects of TRH on the central nervous system of the rabbit
Lundin et al. Analgesic effects of intra-articular morphine during and after knee arthroscopy: a comparison of two methods
IL170743A0 (en) Use of pyridin-2-ylmethylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin
JP3559572B2 (ja) 急性痛および慢性痛用鎮痛剤
US20070105940A1 (en) Method for treating pain
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
US20070259945A1 (en) Method for treating pain
Raghuraman Intrathecal nalbuphine–Will it gain wider acceptance?–A narrative review
WO2009007110A2 (en) Combination of benzyl-4,5-dihydro-1h-imidazole derivative and an opiod recptor ligand
MX2022004610A (es) Uso de derivado de fenilquinolinona o derivado flavonoide para tratamiento del dolor neuropático.
Sinatra et al. Oral and parenteral opioid analgesics for acute pain management
Kamali et al. Analgesic efficacy of bupivacaine alone versus bupivacaine plus dexmedetomidine in penile block for hypospadias surgery
Xuelun et al. Analgesic effect of morphine added to bupivacaine in transversus abdominis plane block for total abdominal hysterectomy
Kim The Effect of Intraarticular Morphine and Clonidine on Postoperative Analgesia after Knee Surgery.
WO2006060190A2 (en) Imidazole derivatives